Buzz
The CDC has disclosed data regarding breakthrough COVID-19 cases among fully vaccinated individuals. While 5,800 people still contracted the virus despite vaccination, this number represents a mere 0.008% of over 66 million vaccinated people, underscoring the vaccine's effectiveness.
What insights do we have about these breakthrough cases?
Current details are sourced from this Wall Street Journal article. The CDC has indicated that additional data will be released in the coming week.
Among the breakthrough cases, 29% showed no symptoms. Just 7% required hospitalization, and only 74 individuals (1.2% of breakthrough cases, or 0.0001% of fully vaccinated people) succumbed to COVID.
These statistics are highly encouraging. They demonstrate the vaccine's strong effectiveness and suggest that even if COVID occurs post-vaccination, the illness is likely to be less severe compared to being unvaccinated. (This principle also applies to the flu vaccine.)
How do these figures align with the efficacy rates, such as Pfizer's 95%, reported in clinical trials?
The metrics differ in calculation, making direct comparison challenging. However, the results are consistent with each other.
In clinical trials, participants are divided into two groups: one receives the actual vaccine, while the other gets a placebo. Over time, as participants go about their daily lives, some contract COVID. Researchers compare the infection rates between the vaccinated group and the placebo group, which determines the trial's efficacy rate.
Real-world effectiveness differs from trial results for several reasons. One key factor is that the trial participants may not fully represent the broader population receiving the vaccine, as they might differ in age, health conditions, and other variables.
Additionally, the prevalence of the virus can fluctuate over time. If overall case numbers decline, breakthrough infections would naturally decrease simply because the virus is less widespread.
In summary, both the trial efficacy rates and the latest data on breakthrough cases confirm that the vaccine performs exceptionally well.
How is it possible for someone to get infected after being vaccinated?
When dealing with millions of people, there will always be rare exceptions. Every vaccine has a documented effectiveness rate. For instance, the measles vaccine is 97% effective, the mumps vaccine is approximately 88% effective, and the flu shot’s effectiveness varies annually, typically falling between 40% and 60%.
Why isn't the effectiveness 100%? Several factors come into play. For instance, not everyone's immune system responds adequately to the vaccine initially. Individuals with compromised immune systems, such as the elderly, may have a weaker response, which is why a high-dose flu vaccine is advised for those over 65.
Another scenario is that even vaccinated individuals can fall ill if exposed to a viral load that surpasses their immune system's capacity. This could result from a significant exposure, like prolonged close contact with a highly infectious person, or due to underlying health issues that compromise immune function.
Lastly, the virus might evolve to outsmart a robust immune response. If a new coronavirus variant has a spike protein that significantly differs from the one targeted by the vaccine, the immune system may fail to identify the threat. This is why variants are alarming, prompting health experts to recommend continued mask usage in public spaces, even post-vaccination.
The CDC is currently collecting data on breakthrough infections to identify commonalities. Are certain individuals more susceptible? Do these infections predominantly stem from specific coronavirus strains or variants? While answers remain elusive, ongoing research may soon shed light on these questions.
